新哒嗪酮类化合物抑制血小板聚集的研究  

Study of new pyridazinones on inhibiting platelet aggregation

作　　者：刘毅敏[1] 覃军[1] 王祥智[1] 赵先英[1] 成晓玲[2] 

机构地区：[1]第三军医大学基础医学部化学教研室,重庆400038 [2]第三军医大学西南医院输血科,重庆400038

出　　处：《第三军医大学学报》2006年第21期2157-2159,共3页Journal of Third Military Medical University

摘　　要：目的观察不同浓度的6-(4-取代苯甲酰氨基苯基)哒嗪酮类化合物对二磷酸腺苷(ADP)诱导血小板聚集的抑制作用。方法将不同浓度的6-(4-取代苯甲酰氨基苯基)哒嗪酮类化合物分别加入人富含血小板血浆(PRP)中,用多功能血小板聚集仪测定ADP诱导的血小板聚集作用。结果该新哒嗪酮类化合物对ADP诱导血小板聚集有剂量依赖性抑制作用,其半数抑制浓度IC50(μmol/L)分别为1.04、2.80、3.01、7.32。结论6-(4-取代苯甲酰氨基苯基)哒嗪酮类化合物具有较强的抑制ADP诱导的血小板聚集作用。Objective To investigate the 6-（4-substituted benzamido phenyl） pyridazinones （0.5, 1.0, 2.0, 4.0, 8.0 μmol/L） on ADP-induced platelet aggregation. Methods After 6-（4-substituted benzamido phenyl） pyridazinones at different concentration was added into the human platelet rich plasma （PRP）, the ADP-induced platelet aggregation was measured by muhifunctional platelet aggregation meter. Results The new 6-（4-substituted phenyl） pyridazinones could inhibit the ADP-induced platelet aggregation in vitro in a dose-dependent manner. The values of IC50were 1.04, 2.80, 3.01 and 7.32 μmol/L respectively. Conclusion 6-（4-substituted benzamido phenyl） pyridazinones have potent activities against platelet aggregation induced by ADP in vitro.

关 键 词：哒嗪酮 血小板聚集 二磷酸腺苷 

分 类 号：R331.143[医药卫生—人体生理学] R973.2[医药卫生—基础医学]